{
  "id": 11428072,
  "title": "H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data",
  "url": "https://urgent.news/2026/10/02/h-c-wainwright-reiterates-nektar-therapeutics-stock-rating-on",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-02T11:42:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-nektar-therapeutics-stock-rating-on-alopecia-data-93CH-4929569"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has maintained a positive outlook on Nektar Therapeutics (NASDAQ:NKTR) stock, reaffirming its Buy rating and setting a price target of $185.00. This decision comes after Nektar presented clinical trial data from the Phase 2b REZOLVE-AA study, which focused on severe-to-very-severe alopecia areata treatment. The data encompassed 52-week treatment results and six-month off-treatment outcomes. Of the eight patients who experienced a SALT (Standing Alopecia Loss Threshold) of 20 or less after 52 weeks of rezpeg treatment, 75% retained the response at four months and 63% at six months post-treatment. Notably, 41% of the 27 patients in the 52-week treatment group achieved an improved response during the six-month off-treatment period, while 22% maintained their initial regrowth. Additionally, among those who participated in the 16-week treatment extension, 29% with less than four years of treatment experience and 30% with four years or more of treatment history attained a SALT of 20 or less by Week 52. SALT 10 or less increased from 7% at Week 52 to 19% during the off-treatment phase, with one patient achieving a SALT of 0. Although Nektar Therapeutics' stock experienced a 22.4% decline to $46.99 on October 1, it remains supported by Wall Street analysts who hold a bullish consensus, with price targets ranging from $50 to $192. However, InvestingPro's Fair Value analysis suggests the stock may be overvalued at its current level.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt",
        "url": "https://urgent.news/2026/10/02/foghorn-therapeutics-stock-price-target-cut-to-5-by-h-c-wainwright-on",
        "published": "2026-10-02T11:42:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}